# Fibrosis Lessens After Metabolic Surgery

> **NCT06374875** · PHASE4 · RECRUITING · sponsor: **Ali Aminian** · enrollment: 120 (estimated)

## Conditions studied

- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
- Non-Alcoholic Fatty Liver Disease
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Liver Fibrosis
- Obesity

## Interventions

- **PROCEDURE:** Metabolic surgery
- **DRUG:** Incretin-Based Therapy

## Key facts

- **NCT ID:** NCT06374875
- **Lead sponsor:** Ali Aminian
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-11
- **Primary completion:** 2029-05-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06374875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06374875, "Fibrosis Lessens After Metabolic Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06374875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*